Aaron Tallent
Freelance Writer and Editor at Freelance
Writer with more than 20 years in communication fields including journalism, media advocacy, health, and sports history. Co-host of the @LoadedGoatPod.
Articles
-
1 week ago |
thezebra.org | Aaron Tallent
ALEXANDRIA, VA-This summer, Alexandria is an official Team Base Camp destination for the FIFA Club World Cup 2025. The city will host Al Ain FC, one of the world’s top clubs from the United Arab Emirates. The team will stay in Alexandria, train at Episcopal High School, and play some games at Audi Field.
-
2 weeks ago |
oncologynewscentral.com | Aaron Tallent
The first-line combination of adagrasib (Krazati) and pembrolizumab (Keytruda) demonstrated efficacy with a manageable safety profile in patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), regardless of PD-L1 status, according to findings from the phase 2 portion of the KRYSTAL-7 study. However, the benefit appears to be greatest in individuals with high PD-L1 scores.
-
3 weeks ago |
oncologynewscentral.com | Aaron Tallent
The use of trastuzumab deruxtecan (T-DXd; Enhertu) has grown significantly during the past five years. Now, interim data from the phase 3 DESTINY-Breast09 trial show that first-line T-DXd plus pertuzumab (Perjeta) significantly improved progression-free survival (PFS) compared with the standard-of-care regimen in patients with HER2-positive locally advanced or metastatic breast cancer.
-
3 weeks ago |
oncologynewscentral.com | Aaron Tallent
Chemotherapy‑induced thrombocytopenia (CIT) is a common adverse event (AE) that can negatively affect care. Now, results from the phase 3 RECITE trial show that romiplostim (Nplate) is effective in treating it in patients with a gastrointestinal (GI) cancer who are receiving oxaliplatin-based chemotherapy. Researchers presented the findings at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and say that the data offer a potential new option for managing CIT (Abstract 12007).
-
3 weeks ago |
oncologynewscentral.com | Aaron Tallent
Adjuvant cisplatin plus radiotherapy has been the standard of care for the last 20 years in patients with resected locally advanced head and neck squamous cell carcinoma (HNSCC) with a high risk for relapse.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 1K
- Tweets
- 6K
- DMs Open
- No
Neoadjuvant chemo with gem/cis may double survival in resectable biliary tract cancer compared to adjuvant therapy, per #GAIN trial data at #ASCO25. It's a promising signal—even with low patient accrual. https://t.co/tDW6a9qx8O
“Do you start writing with an outline?” 📝 Ben #Matlock knew that mapping out what you want to say beats winging it every time. Watch this exchange & learn why I map out every post before typing a word. https://t.co/DjaYNAVsXb
Data from the head & neck cancer #NIVOPOSTOP trial presented at #ASCO25 showed that adding nivolumab to post-op chemoradiotherapy improved 3-year disease-free survival in high-risk HNSCC. https://t.co/TOEJaYsvE9